(f) if so, names of drugs and quantity involved alongwith amount paid on each during the last two years;

(g) what is the provision of DPCO under which each payment was made;

(h) whether there is any balance to be paid; and

(i) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The required details to the extent available will be collected and laid on the Table of the Rajya Sabha.

(c) No, Sir.

(d) The amounts will be recovered as per due process of law.

(e) Yes, Sir.

(f) An amount of Rs. 292.88 lakhs and Rs. 115·00 lakhs was/paid to M/s. IDPL from the DPEA during 1987-88 and 1988-89 respectively in respect of their claims prior to 1986-87. The claims related to bulk drugs of Analgin, Streptomycin Sulphate, Methl Dopa, 6A PA. Phenobarbit one etc.

(g) The payments were made under the provisions of DPCO, 1979 (now DPCO, 1987).

(h) and (i) An amount of Rs. 76 lakhs (approximately) is yet to be paid to M/s. IDPL in respect of their claims mentioned in the reply to part (f) of the question.

Price Control on Bulk Vitamins

139. SHRI MOHD. KHALEELUR RAHMAN: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Vitamin B_1, B_2, B_6 and B_{12} are widely used and are also very important;

(b) whether it is a fact that Kelkar Committee also reiterated their recommendations for inclusion under price control in the supplementary report; and

(c) if so, what is the justification for delaying the action for bringing bulk vitamins under price control?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) : (a) Most of the drugs are widely used and are also important in various ways.

(b) and (c) Some of the recommendations contained in Supplementary report of the Kelkar Committee are yet to be examined.

Price Control on Glybenclamide

140. SHRI MOHD. KHALEELUR RAHMAN: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that his Ministry has price decontrolled Glybenclamide;

(b) whether it is also a fact that there is only one producer of this drug in the country;

(c) whether it is also a fact that they account for 95 per cent of the market of the formulations which is worth rupees five crores and enjoying the monopoly;

(d) whether it is also a fact that the company has increased the prices after decontrol;

(e) if so, what are the earlier and present prices;

(f) what were the basis taken by Kelkar Committee to recommend for price decontrol;

(g) whether it is a fact that Kelkar Committee recommended for inclusion of Polymixin, Methadilazine,

sulphamoxole, Diphenhydramine, Vitamin B_6, B_{12}, B_1, B_2 and a number of other drugs; and

(h) if so, why action has not been taken so far on these recommendations?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) and (c) There is only one major producer of Glybenclamide in this country.

(d) Yes, Sir.

(e) The Company has informed that Glybenclamide bulk drug is only captively used by them for their Daonil tablets; the bulk drug is not sold by them. For the purpose of formulations, while the Company was taking into account the bulk drug price at Rs. 9800/- per kg., the Govt. fixed the price of bulk drug at Rs. 2458/- per kg. on 17-11-1983. The Company, however, continued taking into account the bulk drug price as Rs. 9800/- per kg. for captive use for formulation purposes, in view of stay order in the pending Court case, upto 1987. Thereafter, the Company implemented the price fixed by the Government for Daonil tablets whichwas based on the bulk drug price of Rs. 2458/-per kg. After the exemption of the bulk drug from price control, the Company has fixed the price of bulk drug at Rs. 7800/-per kg. and have consequentially increased the price of the Daonil tablets, from January, 1989 to the erstwhile Retail Price of Rs. 15·62 for 100 (10x10) (Daonil) tablets.

(f) Since it has been deleted by the World Health Organisation (WHO) in their list of essential drugs.

(g) and (h) As indicated in the Supplementary Report of the Kelkar Committee (copies of which are already available in the Parliment Library), the Committee considered certain drugs for possible inclusion in the Second Schedule to DPCO 1987 but could not come to a final view thereon. As per the suggestion of the Committee, the concerned manufactures will be given an opportunity to present their views before final decisions are taken by the Government.

Prices of Decadron formulations

141. SHRIMATI BIJOYA CHAKRAVARTY: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that his Ministry fixed the prices of Decadron formulations;

(b) if so, when and what price of each strength and each pack was fixed under DPCO, 1979 and DPCO, 1987;

(c) what was the price of bulk drug on which the formulation price was fixed each time;

(d) what was the mark up allowed each time;

(e) what is the resultant mark up in terms of quantum by which the company has been benefited;

(f) whether it is a fact that special team appointed to work out the unintended benefits has submitted the report; and

(g) if so, what are the details of their findings?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The details of prices fixed under DPCO, 1987 which are based on the notified price of the bulk drug Dexamethasone by allowing 100% MAPE are given below: The prices of Decadron formulations were not fixed